)--Nexus Pharmaceuticals, LLC announces the U.S Food and Drug Administration (FDA) approval of Tacrolimus Injection 5 mg/mL. Nexus’ Tacrolimus Injection is the first and only vial that will be available.

)--Nexus Pharmaceuticals，LLC宣布美国食品和药物管理局（FDA）批准他克莫司注射液5毫克/毫升。Nexus的他克莫司注射液是第一个也是唯一一个可用的小瓶。

“We are pleased to share the FDA approval of Tacrolimus Injection. Tacrolimus is a critical treatment option for patients requiring immunosuppressive therapy, enhancing their quality of life, and reducing the risk of organ rejection,” says Usman Ahmed, Chief Executive Officer at Nexus Pharmaceuticals, LLC.

Nexus Pharmaceuticals，LLC首席执行官乌斯曼·艾哈迈德（Usman Ahmed）表示：“我们很高兴与FDA分享他克莫司注射液的批准。他克莫司是需要免疫抑制治疗的患者的关键治疗选择，可以提高他们的生活质量，降低器官排斥的风险。”。

“We are proud to provide another reliable and effective treatment that supports successful patient outcomes and overall healthcare efficiency.”.

“我们很自豪能提供另一种可靠有效的治疗方法，支持患者的成功结局和整体医疗保健效率。”。

Tacrolimus Injection 5 mg/mL (Single-Dose Vial) in a 10-pack will be launching soon.

他克莫司注射液5毫克/毫升（单剂量小瓶），10包，即将推出。

About Nexus Pharmaceuticals, LLC

关于Nexus Pharmaceuticals，LLC

: Nexus Pharmaceuticals, LLC, a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor intensive, and more streamlined in practice. Nexus ensures that its high-quality drug products fulfill a critical unmet medical need and deliver dependable life-saving treatment options when and where they’re needed most..

：Nexus Pharmaceuticals，LLC是一家总部位于美国的医疗保健公司，专门从事创新工艺，以使难以制造的特种和仿制药更易于使用，劳动密集程度更低，并且在实践中更加简化。Nexus确保其高质量的药品满足关键的未满足医疗需求，并在最需要的时候和地点提供可靠的挽救生命的治疗选择。。